Cart
sales@molnova.com
LUT014
CAS No. 2274819-46-2
LUT014( —— )
Catalog No. M24036 CAS No. 2274819-46-2
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 107 | In Stock |
|
| 5MG | 177 | In Stock |
|
| 10MG | 258 | In Stock |
|
| 25MG | 435 | In Stock |
|
| 50MG | 622 | In Stock |
|
| 100MG | 887 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLUT014
-
NoteResearch use only, not for human use.
-
Brief DescriptionLUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
-
DescriptionLUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorB-Raf
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2274819-46-2
-
Formula Weight528.49
-
Molecular FormulaC27H19F3N8O
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (94.61 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
-
SMILESCc1ccc2c(Nc3cccc(OC(F)(F)F)c3)nccc2c1Nc1ncccc1-c1ncnc2c1[nH]cn2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Noa Shelach. Novel braf inhibitors and use there of for treatment of cutaneous reactions. WO2019026065A2.
molnova catalog
related products
-
AZ304
AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.
-
SOS1-IN-11
SOS1-IN-11 is an effective inhibitor of SOS1 (IC50 = 30 nM).
-
B-Raf IN 15
B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used in the study of melanoma and cancer, and can be optimized for use as a more effective BRA F inhibitor.
